Polypid Ltd is a biotechnology company focused on developing innovative therapeutic products for surgical procedures. The company harnesses its proprietary polymer technology to create drug-delivery systems that aim to improve patient outcomes by minimizing the risk of infections and enhancing the healing process. Polypid's flagship products are designed to be applied directly at the surgical site, providing controlled release of medications over an extended period. Through its research and development efforts, Polypid seeks to address unmet medical needs in the surgical landscape while promoting safe and effective treatment options for patients. Read More
The Bottom Line: Surgical infections remain a $10B-a-year problem with no effective long-term solution, and hospitals are stuck in a system where prevention often falls short. PolyPid (NASDAQ:PYPD) has developed an innovative technology that directly addresses this gap - and it’s already validated with positive Phase 3 results. For investors, this under-the-radar biotech could be sitting on one of the most compelling opportunities in pharma today, with a current ~$50M market cap that makes the timing especially interesting, as the company approaches commercialization
PolyPid Ltd. (NASDAQ: PYPD), a late-stage biopharma company with a market cap of just $35 million, has unveiled a potentially transformative approach to the red-hot GLP-1 market that could significantly disrupt how weight loss and diabetes medications are delivered to patients.
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion.
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors who missed the live sessions can now access company presentations at their convenience.
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / The Investor Summit Group (ISG), today announced that Ori Warshavsky, Chief Operating Officer - US Operations and Jonny Missulawin, Chief Financial Officer of PolyPid Ltd. (Nasdaq:PYPD), a late-stage biopharma company aiming to improve surgical outcomes will be presenting at this year's Investor Summit Virtual Conference on March 11th, 2025.
